Literature DB >> 17370325

Biological stability of polyurethane modified with covalent attachment of di-tert-butyl-phenol.

Stanley J Stachelek1, Ivan Alferiev, James Fulmer, Harry Ischiropoulos, Robert J Levy.   

Abstract

Polyurethane cardiovascular implants are subject to oxidation initiated surface degradation, which is mediated by monocyte-derived macrophages (MDM); this often leads to surface cracking and device failure. The present studies examined the hypothesis that covalently attaching antioxidant, di-tert-butylphenol (DBP), to the urethane nitrogens of a polyether polyurethane (PU) via bromo-alkylation reactions could prevent this problem. PU was configured with two dosages of DBP, 0.14 mM DBP/g PU of DBP (PU-DBP) and a more highly modified (HM) 0.40 mM DBP/g PU (PU-DBP-HM). THP-1 cells, a human MDM cell line, stimulated with phorbol ester and seeded on PU, PU-DBP, and PU-DBP-HM films were assessed for reactive oxygen species (ROS) production via a fluorescent based dihydrorhodamine-123 assay. Results from these studies showed a significant dose-dependent reduction of ROS levels for THP-1 cells seeded on PU-DBP versus unmodified PU. PU, PU-DBP, or PU-DBP-HM films were implanted into subdermal pouches of Sprague-Dawley rats. Films were explanted after 10 weeks and assessed for oxidative degradation via light and scanning electron microscopy (SEM) and Fourier transformation infrared spectroscopy (FTIR). Light microscopy showed extensive surface cracking, which was confirmed via SEM, on unmodified PU surfaces that was absent in both PU-DBP and PU-DBP-HM explanted films. FTIR analysis showed reduction in oxidation-induced ether crosslinking that was directly related to DBP dosages. It is concluded that modifying PU with the covalent attachment of an antioxidant confers biodegradation resistance in vivo in a dose dependent manner; this effect is likely due to quenching of the ROS generated by the adherent macrophages. Copyright 2007 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17370325     DOI: 10.1002/jbm.a.31215

Source DB:  PubMed          Journal:  J Biomed Mater Res A        ISSN: 1549-3296            Impact factor:   4.396


  7 in total

Review 1.  The use of CD47-modified biomaterials to mitigate the immune response.

Authors:  Jillian E Tengood; Robert J Levy; Stanley J Stachelek
Journal:  Exp Biol Med (Maywood)       Date:  2016-05-10

2.  The effect of CD47 modified polymer surfaces on inflammatory cell attachment and activation.

Authors:  Stanley J Stachelek; Matthew J Finley; Ivan S Alferiev; Fengxiang Wang; Richard K Tsai; Edward C Eckells; Nancy Tomczyk; Jeanne M Connolly; Dennis E Discher; David M Eckmann; Robert J Levy
Journal:  Biomaterials       Date:  2011-03-22       Impact factor: 12.479

3.  Prevention of polyurethane oxidative degradation with phenolic antioxidants covalently attached to the hard segments: structure-function relationships.

Authors:  Stanley J Stachelek; Ivan Alferiev; Masako Ueda; Edward C Eckels; Kevin T Gleason; Robert J Levy
Journal:  J Biomed Mater Res A       Date:  2010-09-01       Impact factor: 4.396

Review 4.  Biomaterial applications in cardiovascular tissue repair and regeneration.

Authors:  Mai T Lam; Joseph C Wu
Journal:  Expert Rev Cardiovasc Ther       Date:  2012-08

5.  Correlating macrophage morphology and cytokine production resulting from biomaterial contact.

Authors:  Hyun-Su Lee; Stanley J Stachelek; Nancy Tomczyk; Matthew J Finley; Russell J Composto; David M Eckmann
Journal:  J Biomed Mater Res A       Date:  2012-07-30       Impact factor: 4.396

Review 6.  Biomaterial Approaches for Stem Cell-Based Myocardial Tissue Engineering.

Authors:  Josh Cutts; Mehdi Nikkhah; David A Brafman
Journal:  Biomark Insights       Date:  2015-06-01

Review 7.  An Insight into the Structural Diversity and Clinical Applicability of Polyurethanes in Biomedicine.

Authors:  Laura-Cristina Rusu; Lavinia Cosmina Ardelean; Adriana-Andreea Jitariu; Catalin Adrian Miu; Caius Glad Streian
Journal:  Polymers (Basel)       Date:  2020-05-24       Impact factor: 4.329

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.